NCT06682572

A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Japanese Patients

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Verastem, Inc. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will confirm the safety and efficacy of avutometinib in combination with defactinib in Japanese patients with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Detailed description

This is a multi-center, open label Phase 2 study designed to evaluate safety and tolerability and confirm efficacy by BICR of avutometinib in combination with defactinib in Japanese patients with molecularly profiled recurrent LGSOC.

Conditions

• Low Grade Serous Ovarian Cancer
• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Avutometinib (VS-6766) + Defactinib (VS-6063)	combination therapy

Timeline

• Start date: 2024-10-30
• Primary completion: 2025-12-01
• Completion: 2027-10-01
• First posted: 2024-11-12
• Last updated: 2025-12-17

Locations

5 sites across 1 country: Japan

Regulatory

• FDA-regulated drug study